Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KYNAMRO vs NIACOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Kynamro (mipomersen) is an antisense oligonucleotide that specifically binds to the m RNA of apolipoprotein B-100 (apo B-100), inhibiting its translation and reducing the production of apo B-100-containing lipoproteins, including LDL, VLDL, and Lp(a).
Niacin (nicotinic acid) reduces VLDL and LDL synthesis by inhibiting lipolysis in adipose tissue, decreasing free fatty acid flux to the liver, and inhibiting hepatic triglyceride synthesis. It also increases HDL by reducing catabolism of apolipoprotein A-I.
Adjunct to lipid-lowering medications and diet to reduce LDL-C, apo B, total cholesterol, and non-HDL-C in patients with homozygous familial hypercholesterolemia (Ho FH)
Adjunct to diet for reduction of elevated total cholesterol, LDL-C, apo B, and triglyceride levels, and to increase HDL-C in primary hypercholesterolemia and mixed dyslipidemia,Adjunct to diet for reduction of risk of recurrent myocardial infarction in patients with coronary artery disease and hypercholesterolemia,Adjunct to diet for slowing progression of coronary atherosclerosis,Off-label: treatment of pellagra (niacin deficiency)
Kynamro (mipomersen) is administered subcutaneously at a dose of 200 mg once weekly.
Initial: 250 mg orally once daily after evening meal; titrate up by 250–500 mg/day every 2–4 weeks. Maintenance: 1–2 g/day in divided doses (2–3 times daily). Maximum: 6 g/day.
Terminal elimination half-life is approximately 28-31 days (range 21-40 days) in patients with homozygous familial hypercholesterolemia, supporting weekly subcutaneous dosing.
20–45 minutes for immediate-release niacin; terminal half-life of main metabolites (nicotinuric acid) is approximately 1.5–4 hours; short half-life necessitates multiple daily dosing for lipid effects
Primarily metabolized by endonucleases and exonucleases. Not a substrate for CYP450 enzymes.
Hepatic metabolism via two pathways: conjugation with glycine to form nicotinuric acid (major, low-affinity high-capacity) and oxidation to N-methylnicotinamide and other metabolites (minor, high-affinity low-capacity). Enzymes involved: nicotinamide N-methyltransferase (NNMT) and aldehyde oxidase.
Primarily hepatobiliary elimination; less than 1% excreted unchanged in urine. Mipomersen is metabolized by endonucleases and exonucleases to shorter oligonucleotides, which are excreted in bile and feces.
Renal: 60-88% as unchanged drug and metabolites after oral administration; fecal: <2%
Greater than 90% bound to plasma proteins, predominantly albumin.
<20% bound to albumin; minimal binding to other plasma proteins
Approximately 9.6 L/kg, indicating extensive tissue distribution (e.g., liver, kidney).
0.5–0.7 L/kg; indicates distribution into total body water and some tissue binding
Subcutaneous administration: approximately 90% bioavailability; not administered intravenously clinically.
Oral immediate-release: 60–76% (variable due to first-pass metabolism); sustained-release: lower bioavailability (50–60%) due to increased presystemic metabolism
No dose adjustment is required for mild to moderate renal impairment (Cr Cl >30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or dialysis; use with caution.
No specific adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation; consider reducing dose or prolonging interval.
Contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). No dose adjustment recommended for mild hepatic impairment (Child-Pugh class A).
Contraindicated in Child-Pugh class B and C; use with caution in mild impairment (Child-Pugh A) with dose reduction of 50% initially.
Safety and efficacy in pediatric patients have not been established; not recommended for use in patients under 18 years of age.
For hyperlipidemia (off-label): Initial 50–100 mg/kg/day orally divided into 2–3 doses; titrate over 4–6 weeks up to 200–300 mg/kg/day; maximum 6 g/day. Not recommended in children <2 years.
No specific dose adjustments for elderly patients; clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Start at lowest dose (250 mg daily); titrate slowly due to increased risk of flushing, hypotension, and hepatotoxicity; monitor liver function and glucose closely.
Risk of hepatotoxicity: Kynamro can cause elevations in serum transaminases and hepatic steatosis. Monitor liver function before and during treatment. Do not use in patients with moderate or severe hepatic impairment.
None.
Hepatotoxicity: monitor ALT, AST, alkaline phosphatase, and total bilirubin before each dose; discontinue if clinically significant toxicity occurs.,Hepatic steatosis: may cause fatty liver; advise patients to report symptoms of liver injury.,Injection site reactions: common and may be severe.,Flu-like symptoms: common; may require symptomatic treatment.,Allergic reactions: including angioedema and urticaria.,Immune system effects: possible development of anti-drug antibodies and platelet count reductions.
Hepatotoxicity: elevated liver enzymes, hepatitis; discontinue if persistent elevations occur,Flushing: prostaglandin-mediated, can be reduced by taking aspirin prior; tolerance develops,Hyperuricemia: may precipitate gout,Hyperglycemia: may increase blood glucose; use with caution in diabetes,Peptic ulcer disease: reactivation may occur,Hypotension: can occur, especially with vasoactive drugs
Moderate or severe hepatic impairment (Child-Pugh class B or C),Hypersensitivity to mipomersen or any component of the formulation,Active liver disease or unexplained persistent elevations of serum transaminases
Hypersensitivity to niacin or any component of formulation,Significant or unexplained hepatic dysfunction,Active peptic ulcer disease,Arterial hemorrhage
Avoid high-fat meals before and after injection. Take KYNAMRO at least 2 hours after any food and at least 1 hour before the next meal to minimize gastrointestinal side effects. No specific food-drug interactions known; however, the drug can increase hepatic fat, so a low-fat diet is generally recommended.
Avoid high-fat meals as they may increase risk of flushing. Take with low-fat snack. Alcohol and hot drinks can exacerbate flushing.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no fetal harm was observed; however, caution is advised. KYNAMRO is not recommended during pregnancy unless clearly necessary.
FDA Pregnancy Category C. Niacin is not recommended for use in pregnant women due to potential fetal harm, though no well-controlled studies exist. In animal studies, high doses have caused fetal abnormalities. First trimester: Avoid use due to theoretical risk of teratogenicity. Second and third trimesters: Use only if clearly needed, as niacin can cause vasodilation and potential hypotension, which may reduce uteroplacental perfusion.
It is unknown if KYNAMRO is excreted in human milk. No M/P ratio available. A risk to the breastfed infant cannot be excluded; decision to discontinue breastfeeding or drug should consider importance of drug to mother.
Niacin is excreted into human breast milk in minimal amounts; M/P ratio unknown. The American Academy of Pediatrics considers niacin compatible with breastfeeding. However, high maternal doses may lead to adverse effects in the infant due to potential accumulation. Caution is advised; monitor infant for flushing or gastrointestinal disturbances.
No pharmacokinetic studies in pregnancy. No specific dose adjustment recommended; use only if potential benefit justifies potential risk. Standard dose: 200 mg subcutaneously once weekly.
No specific dose adjustments recommended due to lack of pharmacokinetic studies in pregnant women. However, physiological changes in pregnancy (increased plasma volume, renal clearance) may reduce niacin levels, potentially requiring dose increase. Use the lowest effective dose and avoid extended-release formulations due to higher hepatotoxicity risk. Usual adult doses (500-2000 mg/day) may be used with caution.
KYNAMRO (mipomersen) is an antisense oligonucleotide for homozygous familial hypercholesterolemia (Ho FH). It reduces LDL-C by inhibiting apo B-100 synthesis. Monitor for hepatotoxicity; require ALT, AST, alkaline phosphatase, and bilirubin before each dose. Injection site reactions are common; rotate sites. Consider a statin first-line in Ho FH if tolerated; mipomersen is adjunctive. Avoid in patients with significant liver disease or unexplained persistent transaminase elevations. Do not use in pregnancy due to risk of embryofetal toxicity.
Niacor (niacin) can cause profound flushing, which may be mitigated by taking aspirin 30 minutes prior or using extended-release formulations. Monitor liver function and blood glucose, as niacin can elevate transaminases and worsen glycemic control. Patients with gout may experience increased uric acid levels.
KYNAMRO is a weekly injection under the skin for homozygous familial hypercholesterolemia.,You must have blood tests to check your liver before each dose.,Common side effects include injection site redness, swelling, pain, or itching; flu-like symptoms; and nausea.,Do not take KYNAMRO if you are pregnant or planning to become pregnant; use effective contraception.,Take KYNAMRO on the same day each week, at least 2 hours after a meal and at least 1 hour before any food or other oral medications.,Store KYNAMRO in the refrigerator; do not freeze. Allow to warm to room temperature for 30 minutes before injecting.,Contact your doctor immediately if you experience yellowing of skin or eyes, dark urine, or severe abdominal pain.
Take with food to reduce stomach upset.,Do not crush or chew extended-release tablets.,Flushing is common and may decrease with continued use.,Avoid alcohol and hot beverages near dosing time to reduce flushing.,Report unexplained muscle pain, tenderness, or weakness.,Monitor blood sugar if diabetic.,Do not substitute with dietary supplements without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KYNAMRO vs NIACOR, answered by our medical review team.
KYNAMRO is a Antilipemic that works by Kynamro (mipomersen) is an antisense oligonucleotide that specifically binds to the m RNA of apolipoprotein B-100 (apo B-100), inhibiting its translation and reducing the production of apo B-100-containing lipoproteins, including LDL, VLDL, and Lp(a).. NIACOR is a Antilipemic agent that works by Niacin (nicotinic acid) reduces VLDL and LDL synthesis by inhibiting lipolysis in adipose tissue, decreasing free fatty acid flux to the liver, and inhibiting hepatic triglyceride synthesis. It also increases HDL by reducing catabolism of apolipoprotein A-I.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KYNAMRO and NIACOR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KYNAMRO is: Kynamro (mipomersen) is administered subcutaneously at a dose of 200 mg once weekly.. The standard adult dose of NIACOR is: Initial: 250 mg orally once daily after evening meal; titrate up by 250–500 mg/day every 2–4 weeks. Maintenance: 1–2 g/day in divided doses (2–3 times daily). Maximum: 6 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KYNAMRO and NIACOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KYNAMRO is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no fetal harm was observed; however, caution is advised. KYNAMRO is not recommended durin. NIACOR is classified as Category C. FDA Pregnancy Category C. Niacin is not recommended for use in pregnant women due to potential fetal harm, though no well-controlled studies exist. In animal studies, high doses ha. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.